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Introduction
Triptans, 5-HT1B/1D agonists, have been recognised by
both migraineurs and headache specialists as the treatment
of choice for acute migraine therapy [1, 2]. Currently
there are 7 available triptans, all of which have been stud-
ied in numerous randomised controlled trials (RCTs)
[3–5]. These RCTs have provided essential data on the
efficacy and tolerability of triptans compared with place-
bo, including long-term data and some head-to-head com-
parisons between triptans. Comprehensive, indirect com-
parative data on triptans are available from a meta-analy-
sis of 53 RCTs [6].
Although the published literature on triptans in RCTs
is extensive, RCTs cannot collect all of the data relevant
to use in routine clinical practice. Therefore, it should not
be automatically assumed that real-world experience with
triptans will exactly mirror RCT findings. Postmarketing
surveillance (PS) studies can provide important informa-
tion on the use of triptans in routine clinical practice [7].
This article will review the strengths and limitations of
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Abstract Randomised controlled tri-
als cannot collect all the data rele-
vant for use in everyday clinical
practice because drug exposure is
limited, endpoints are restricted and
some patient populations are exclud-
ed. Postmarketing surveillance (PS)
studies can add important informa-
tion for real-world clinical practice.
Acute migraine therapy with
almotriptan 12.5 mg was evaluated
in 4 PS studies, 2 conducted in
Spain, 1 in Germany and 1 in
France. Almotriptan was associated
with a high rate of treatment
response and was well tolerated in
all 4 studies. In the Spanish and
German studies, 2-hour pain-relief,
2-hour pain-free, and sustained pain-
free rates were enhanced when
patients treated mild pain. Patient
satisfaction with almotriptan,
assessed in the German and French
studies, was high and the majority of
patients preferred almotriptan to their
previous acute migraine therapy. In
conclusion, PS studies augment our
knowledge of antimigraine therapy,
giving a more complete picture of
how such agents work in the general
population.
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RCTs and PS studies with reference to triptans and, as an
example, will describe the findings from PS studies of
almotriptan conducted in Spain, Germany and France.
The merits of randomised controlled trials and postmar-
keting surveillance studies of acute treatments for
migraine
When clinical data are ranked according to value and
importance in evidence-based clinical reviews and treat-
ment guidelines, findings from high-quality RCTs usually
receive the highest ranking, along with meta-analyses.
The strength of data from such sources is considered
greater than that from clinical cohort studies, high-quality
epidemiologic studies and case-control studies [8]. The
results of RCTs are greatly valued because the protocols
are designed to minimise bias through randomisation of
patients, blinding of patients and investigators to study
treatments, use of control agents, and predefinition of end-
points. In addition, rigorous follow-up is performed to
obtain the most complete data set possible from each
patient [7]. However, RCTs also have limitations because
these protocols impose restrictions on data acquisition.
The basic features of RCT and PS study design, provided
in Table 1, illustrate these limitations.
Overall, patients have less drug exposure in RCTs
compared with PS surveillance studies, particularly if the
study drug is a rescue medication or acute therapy. Fewer
patients are enrolled in RCTs compared with PS studies,
and the use of controls in RCTs decreases the number of
patients receiving the drug of interest [7].
Endpoints in RCTs, which are predefined, are usually
constrained by requirements for drug registration. For
example, many early RCTs of triptans included 2-hour
pain relief (2-h PR) as a primary endpoint. The 2-h PR
endpoint requires patients to take their medication when
headache pain is moderate to severe in intensity so that a
reduction of 2 points on a 4-point headache pain scale
(3=severe, 2=moderate, 1=mild and 0=no pain) can be
observed [9]. There are several arguments against the use
of 2-h PR as a primary endpoint. First, accumulating data,
including those from post hoc analyses of protocol viola-
tors in RCTs of triptans, suggest that triptan efficacy may
be optimised by treating when headache pain is mild
rather than waiting until it becomes moderate to severe in
intensity [10–14]. Second, when using this endpoint,
reduction from severe pain to none and from moderate to
mild pain are ranked as equivalent treatment responses.
Third, this endpoint does not reflect patients’ therapeutic
goals. Survey data indicate that most migraineurs want
acute therapies to provide complete freedom from pain
[15, 16]. Finally, the discriminatory power of the 2-h PR
endpoint is poor, as shown by the lack of difference in 2-h
PR rates between triptans and analgesics in many RCTs
[17]. Because they are not constrained by drug registra-
tion requirements, PS studies can include a wider variety
of endpoints that are meaningful to patients such as mea-
sures of satisfaction with therapy.
Of particular note is the difference in the patient pop-
ulations between RCTs and PS studies. A number of key
patient groups often are excluded from RCTs, that is, the
elderly, children, those with comorbid conditions, those
using concomitant medications and other patients at high-
er risk for adverse events (AEs). Because migraine affects
more women than men, more young and middle-aged
adults than other age groups, and more whites than mem-
bers of other races [18], the population of migraineurs
might mistakenly be thought to be homogenous.
In reality, however, migraine affects a wide variety of
patients. One reason is that it affects such a large segment
of the population, including an estimated 10%–12% of the
population of the western world [18, 19]. Another factor
contributing to the diversity of the migraineur population
is the association of migraine with a variety of comorbid
conditions such as other neurologic conditions, affective
disorders and rheumatologic diseases [19–23]. An advan-
Table 1 Properties of randomised controlled trials vs. postmarketing surveillance studies [7]
Parameter Randomised controlled trial Postmarketing surveillance study
Randomisation Yes No
Blinding Double-blind Open-label
Control Placebo or active None
Outcome measurement Predefined No predefinition (sometimes)
Follow-up Rigorous Incomplete
Patients




tage to the inclusion of a diverse patient population in PS
studies is that it allows for the identification of differences
in drug efficacy, tolerability and safety in individuals with
different pharmacogenetics, immune systems, drug
metabolism and drug-drug interactions [24]. The longer
duration of PS studies allows for the detection of rarer
AEs and delayed AEs.
A RCT tests the hypothesis that treatment with one
active agent is better than treatment with another active
agent or placebo. The results will be valid internally, that
is, within the context of the trial, if the trial is properly
designed and executed. Most well-designed, randomised,
double-blind trials with sufficient statistical power will
meet the challenge of internal validity. The more common
issue complicating the interpretation of RCTs, however,
is external validity, that is, can the findings from a trial be
extrapolated to the general population of patients with
this disorder. Are the patients being treated in this trial
similar to the migraine patients outside of this trial with
regard to age, gender, race, comorbid disorders, triptan
experience and level migraine-associated disability [25]?
Does the different level of care provided in this trial
(higher number of visits and measurement scales used,
review of informed consent documents explaining the
benefits and risks of treatment, the existence of a placebo
arm) change the study outputs? It may not be appropriate
to generalise the results of RCTs for a given drug to the
entire population of patients who might use that agent
[7]. PS studies, with their more diverse range of partici-
pants, may be more likely to meet the standards for exter-
nal validity.
Postmarketing surveillance studies conducted in Spain
Two multicentre, open-label, 3-month patients’ follow-up
observational PS studies that assessed the efficacy and tol-
erability of acute migraine therapy with almotriptan 12.5
mg were conducted in Spain [26, 27]. These studies had
identical protocols except for the patient recruitment sites.
The first study enrolled approximately 1000 patients
receiving headache therapy from neurologists. The second
study included about 2000 patients receiving treatment for
headache from primary care physicians (PCPs). In each
study, approximately 4000 attacks were treated. Patient
demographics were similar in these 2 studies except for a
greater frequency of migraine attacks in the group being
treated by neurologists and their greater use of prophylac-
tic migraine medications compared to those being treated
by PCPs (35.1% vs. 25.3%).
Almotriptan was associated with a high rate of treat-
ment response in both studies (Table 2). The rates for 2-h
PR, 2-hour pain free (2-h PF) and sustained pain free
(SPF, pain free at 2 h after dosing and no headache recur-
rence or use of rescue medication for up to 24 h after dos-
ing) were found to be greater in the PCP patient study
compared with the neurology patient study. Rates for 2-h
PF and SPF were also higher for the PCPs’ patients com-
pared with the neurologists’ patients when these endpoints
were analysed according to headache severity at time of
dosing. In both studies, greater response rates were
obtained when patients took their medication when
headache pain was mild compared with treatment when
pain was moderate or severe.
Table 2 Two-hour pain-relief, 2-hour pain-free and sustained pain-free rates in postmarketing surveillance studies of
almotriptan conducted in Spain and Germany
Pain intensity at time of dosing
All attacks Mild Moderate/severe Moderate Severe
Spanish PS studies
Neurologists’ patients [7, 26, 27]
2-h PR 65.5
2-h PF 26.6 59.7 23.3
SPF 18.6 43.9 16.1
PCPs’ patients [7, 26, 27]
2-h PR 86.6
2-h PF 50.5 80.5 48.5
SPF 44.8 70.9 43.0
German PS study [7, 28]
2-h PR 84.5 96.3 74.0
2-h PF 41.5 89.3 55.3 22.1
PS, postmarketing surveillance; 2-h PR, 2-hour pain relief; 2-h PF, 2-hour pain free; SPF, sustained pain free
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The overall incidence of AEs reported in these 2 trials
was low: 3.9% of patients in the neurologist study and
1.1% in the PCP study. The most commonly reported AEs
were somnolence (0.9%), nausea (0.8%) and dizziness
(0.7%) in the neurologist study, and nausea (0.4%),
abdominal pain (0.2%) and somnolence (0.2%) in the PCP
study. Most AEs were mild to moderate in intensity.
Postmarketing surveillance study conducted in Germany
The PS study of almotriptan efficacy and tolerability con-
ducted in Germany was a multicentre, open-label obser-
vational study including 899 migraineurs recruited by 307
neurologists and PCPs [28]. Migraineurs who had never
used almotriptan received treatment with this agent at a
dose of 12.5 mg for up to 3 migraine attacks (preferably
consecutive attacks). Data were obtained for the treatment
of 2131 attacks, with more than half of the patients treat-
ing 3 attacks and about one-quarter treating 2 attacks.
Almotriptan 12.5 mg was associated with a 2-h PR rate
of 84.5% and a 2-h PF rate of 41.5% for all attacks (Table
2). Analysis of 2-h PF according to headache intensity at
time of treatment showed a much higher rate for treatment
when headache pain was mild compared with that for ther-
apy delayed until pain was moderate or severe.
Almotriptan treatment was associated with relief from
nausea, vomiting and photophobia in greater than 90% of
attacks with these associated symptoms.
A total of 500 patients provided outcomes for 3
attacks; these data were used to assess consistency of
treatment response and baseline intensity of headache
pain and other migraine-associated symptoms. Consisten-
cy was defined as successful treatment of ≥2 out of 3
attacks with success referring to a decrease in pain inten-
sity from moderate or severe to mild or none at 2 h after
treatment. The consistency rate for almotriptan 12.5 mg
was 87.3%, and 69.3% of patients achieved treatment suc-
cess in 3 out of 3 attacks. Analysis of baseline pain and
associated symptoms showed that the intensity of
headache pain and symptoms of nausea, vomiting and
photophobia at the time of treatment decreased from
attack 1 to 3, suggesting that patients learned to treat their
migraines earlier (Fig. 1).
The incidence of AEs was 1.1% of patients with a
total of 29 events across all 2131 migraine attacks. A total
of 21 of the 29 AEs were deemed possibly or probably
related to therapy. None of the AEs were serious. The
most common AEs were fatigue (0.3% of patients) and
nausea (0.2% of patients).
Physicians’ global assessment of almotriptan efficacy
was “good” or “very good” for 87.6% of the patients (Fig. 2),
and their global assessment of almotriptan tolerability was
“good” or “very good” for 96.3% of patients. Patients’ rat-
ings of their satisfaction with treatment were high, with
more than half (54.7%) indicating that they were very sat-
isfied with almotriptan and about another one-third
(33.8%) stating that they were satisfied with almotriptan.
Compared with their previous acute migraine therapies,
80.3% of patients considered almotriptan to be more
effective, 13% found no difference between almotriptan
and their previous migraine therapy, and 5.1% thought
that the previous migraine treatment was better. Analysis
according to previous triptan usage showed that almotrip-
tan was preferred by 80.5% of naratriptan users, 73.7% of
sumatriptan users, 71.4% of rizatriptan users and 69.8% of
zolmitriptan users.
Fig. 1 Intensity of headache pain and migraine-associated symp-
toms at time of treatment with almotriptan 12.5 mg for 500 patients
in the German postmarketing surveillance study for whom data on
3 attacks were available [28]
Fig. 2 Physicians’ global assessment of efficacy and tolerability
and patients’ overall assessment of treatment satisfaction from the
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Postmarketing surveillance study conducted in France:
MISTRAL
The MIgraine – Satisfaction with Treatment: Reality with
ALmogran (MISTRAL) was an open-label, multicentre
study of almotriptan 12.5 mg conducted in France that
assessed efficacy, tolerability and patient satisfaction
among migraineurs with a long history of migraine who
were dissatisfied with their current acute therapy [29].
Data from 434 patients (342 evaluable for efficacy),
57.6% of whom had been using a triptan, were obtained
for 929 attacks (up to 3 consecutive attacks/patient) by
154 neurologists. The patients included in the MISTRAL
study probably suffered from a more severe disease than
the general population of migraineurs, as indicated by the
high proportion of patients receiving migraine prophylax-
is (34.3%) and their receiving treatment from neurologists
rather than PCPs.
Baseline pain intensity was mild in 15% of attacks,
moderate in 50% and severe in 35%. At 2 hours after treat-
ment, headache pain had disappeared in 33.4% of attacks,
was mild in 26.9%, moderate in 19.5% and severe in 8.7%
(9.4% of patients were asleep at this point) (Fig. 3). The
rate of pain relief was 69.3%, the recurrence rate (within
24 h) was 28.4% and emergency analgesics were used in
20.9% of attacks by 32.6% of patients.
AEs were reported by 29.8% of patients. The most
common AEs were nausea (8.5%), fatigue (6.4%) and
somnolence (5.8%). Treatment-related AEs occurred in
23.7% of patients. The rate of AE-related discontinuation
was 2.6% of patients.
Patient satisfaction with almotriptan treatment was
high in the MISTRAL study. The proportion of patients
who were very satisfied/satisfied overall with therapy was
69% (Fig. 4). Data collected using a 4-item questionnaire
developed by the National Agency for Accreditation and
Evaluation in Health (ANAES) for determining the need
to change acute migraine therapy [30] revealed that
almotriptan 12.5 mg was associated with an increased
proportion of patients experiencing significant relief at 2
h (69.3% vs. 26.6%), tolerating the medication well
(91.2% vs. 76.0%), able to rapidly resume normal activi-
ties (70.5% vs. 24.9%) and taking only 1 dose (59.4% vs.
28.1%) compared with previous therapies (Fig. 5). At
study end, 73.1% of patients had at least 1 additional
“Yes” response on the ANAES questionnaire compared to
study onset and 40.9% of patients answered “Yes” to all 4
questions; 56.4% of patients expressed a preference for
continuing almotriptan therapy.
Fig. 3 Headache pain intensity 2 h after treatment with almotriptan
12.5 mg in the French postmarketing surveillance study [29]
Fig. 4 Patients’ global satisfaction with treatment with almotriptan
12.5 mg at the study end in the French postmarketing surveillance
study [29]
Fig. 5 Proportion of patients answering “yes” to each of the ques-
tions in the National Agency for Accreditation and Evaluation in
Health (ANAES) questionnaire at study inclusion and at study end






























significant relief 2 hours after taking
your migraine treatment?
Is your treatment well tolerated?
When you take your treatment, can you
quickly return to your normal social,
family and professional activities?
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Discussion
A variety of different types of trials and analyses are need-
ed to obtain a complete view of the efficacy and tolerabili-
ty of a given therapeutic agent. Although RCTs provide
internally valid data with minimal bias, these studies do not
provide all of the information needed for a complete picture
of a drug’s efficacy and tolerability. PS studies can include
endpoints not required for drug registration, collect data on
alternative dosing regimens, and enrol patients who might
not be eligible for RCTs. As a result, PS studies can add
valuable information on real-world clinical experience.
The European PS studies presented here demonstrate
that almotriptan was associated with a high rate of treat-
ment response in the community setting. The Spanish and
German studies assessed efficacy using the conventional
acute migraine therapy endpoint 2-h PR along with 2-h PF
and SPF. The 2-h PF and SPF endpoints are highly relevant
to migraineurs because they incorporate top-ranked treat-
ment attributes: rapid response, and complete freedom
from pain in 2-h PF, and rapid response, complete freedom
from pain, and no headache recurrence in SPF [15].
In the Spanish PS studies, 2-h PR, 2-h PF and SPF
were higher for patients recruited by PCPs compared with
those for patients recruited by neurologists. These find-
ings suggest that patients receiving therapy for migraine
from neurologists, who were suffering from more frequent
migraine attacks, may be more difficult to treat than those
receiving therapy from PCPs. However, the rates for 2-h
PR, 2-h PF and SPF observed for the neurologists’
patients indicate that almotriptan was efficacious in that
population as well.
The Spanish and German PS studies showed that the
efficacy of almotriptan was greater when the medication
was taken when headache pain was mild compared with
treatment delayed until pain was moderate or severe, con-
sistent with retrospective findings from RCTs of almotriptan
[11–14]. Findings from the German PS study showed that
over 3 attacks there was a tendency to treat headache pain
and associated symptoms at increasingly milder intensity on
average. This result suggests that patients were learning to
recognise and treat migraine during earlier stages.
Although there is increasing recognition that triptans
appear to be most efficacious when used during the mild
stage of migraine headache pain, patients may be more
reluctant to treat mild than moderate or severe pain
because of tolerability issues. A survey of greater than
1000 migraineurs found that concern about AEs had cau-
sed two-thirds of them to delay or avoid using a prescrip-
tion medication for migraine [31]. The AE profile of al-
motriptan, shown in RCTs to be similar to that of placebo
[11–14, 32] and validated as “very good” in PS studies,
and its demonstrated efficacy for treating migraine
headache during the mild stage [11–14, 32], make al-
motriptan an ideal triptan for early migraine intervention.
Almotriptan was associated with a high level of patient
satisfaction in the German and French studies. This was
especially noteworthy in the French study as inclusion cri-
teria required patients to be dissatisfied with their current
acute therapy. Furthermore, the majority of patients in
these studies preferred almotriptan to their previous acute
migraine therapy. These findings are consistent with the
results of the meta-analysis of 53 RCTs of oral triptans,
which showed that on the basis of efficacy, consistency
and tolerability, almotriptan 12.5 mg was 1 of 3 triptan
doses associated with the greatest likelihood of consistent
treatment success [6].
In summary, while RCTs provide the highest levels of
quality evidence and the least bias, PS studies provide
valuable data on real-world experience with agents such
as triptans. They can have greater external validity com-
pared to RCTs as they generally involve a more diverse
yet representative segment of the general population of
individuals with migraine. PS studies often measure end-
points that are more important to patients, in addition to
investigating patient satisfaction and preference. PS stud-
ies of almotriptan showed this agent to be efficacious,
associated with a high level of patient satisfaction, and
well tolerated for the acute treatment of migraine. The
efficacy of almotriptan in this setting was greatest when
treatment was initiated during mild headache pain. In con-
clusion, PS studies add to our body of knowledge of
antimigraine therapy, giving a more complete picture of
how such agents work in real-world settings.
References
1. Silberstein SD (2000) Practice parame-
ter: evidence-based guidelines for
migraine headache (an evidence-based
review): report of the Quality
Standards Subcommittee of the
American Academy of Neurology.
Neurology 55:754–762
2. Robbins L (2002) Triptans versus anal-
gesics. Headache 42:903–907
3. Diener HC, Kaube H, Limmroth V
(1999) Antimigraine drugs. J Neurol
246:515–519
4. Goadsby PJ, Lipton RB, Ferrari MD
(2002) Migraine-current understanding
and treatment. N Engl J Med
346:257–270
5. Silberstein SD (2004) Migraine. Lancet
363:381–391
33
6. Ferrari MD, Roon KI, Lipton RB,
Goadsby PJ (2001) Oral triptans (sero-
tonin 5-HT(1B/1D) agonists) in acute
migraine treatment: a meta-analysis of
53 trials. Lancet 358:1668–1675
7. Pascual J (2005) Efficacy and tolera-
bility of almotriptan in postmarketing
surveillance studies. Eur Neurol
53[Suppl 1]:34–40
8. American Academy of Family
Physicians (2004) Levels of evidence
in AFP. Available at:
http://www.aafp.org/x17444.xml.
Accessed September 26, 2004
9. Edmeads J (2005) Defining response
in migraine: which endpoints are
important? Eur Neurol 53[Suppl
1]:22–28
10. Cady RK, Sheftell F, Lipton RB et al
(2000) Effect of early intervention with
sumatriptan on migraine pain: retro-
spective analyses of data from three
clinical trials. Clin Ther 22:1035–1048
11. Pascual J, Cabarrocas X (2002)
Within-patient early versus delayed
treatment of migraine attacks with
almotriptan: the sooner the better.
Headache 42:28–31
12. Pascual J (2002) Clinical benefits of
early triptan therapy for migraine.
Headache 42[Suppl 1]:S10–S17
13. Mathew NT (2003) Early intervention
with almotriptan improves sustained
pain-free response in acute migraine.
Headache 43:1075–1079
14. Dowson AJ, Massiou H, Lainez JM,
Cabarrocas X (2004) Almotriptan
improves response rates when treat-
ment is within 1 hour of migraine
onset. Headache 44:318–322
15. Lipton RB, Hamelsky SW, Dayno JM
(2002) What do patients with migraine
want from acute migraine treatment?
Headache 42[Suppl 1]:S3–S9
16. Davies GM, Santanello N, Lipton R
(2000) Determinants of patient satis-
faction with migraine therapy.
Cephalalgia 20:554–560
17. Lipton RB, Bigal ME, Goadsby PJ
(2004) Double-blind clinical trials of
oral triptans vs other classes of acute
migraine medication – a review.
Cephalalgia 24:321–332
18. Breslau N, Rasmussen BK (2001) The
impact of migraine: epidemiology, risk
factors, and co-morbidities. Neurology
56[Suppl 1]:S4–S12
19. Lipton RB, Stewart WF (1998)
Migraine headaches: epidemiology and
comorbidity. Clin Neurosci 5:2–9
20. Breslau N, Merikangas K, Bowden CL
(1994) Comorbidity of migraine and
major affective disorders. Neurology
44[Suppl 7]:S17–S22
21. Joish VN, Cady PS, Bennett DM,
Harris RB (2000) An epidemiological
case-control study of migraine and its
associated comorbid conditions. Ann
Epidemiol 10:460
22. Shechter AL, Lipton RB, Silberstein
SD (2001) Migraine comorbidity. In:
Silberstein SD, Lipton RD, Dalessio
DJ (eds) Wolff’s headache and other
headache pain. Oxford University
Press, New York, pp 108–118
23. Ruoff GE (2004) Migraine comorbidi-
ty: consequent pharmacologic strate-
gies for treatment. Headache Pain
15:9–15
24. Atuah KN, Hughes D, Pirmohamed M
(2004) Clinical pharmacology: special
safety considerations in drug develop-
ment and pharmacovigilance. Drug Saf
27:535–554
25. Lipton RB (2001) Studying the
migraine studies: methodological issues
in comparative trials of acute medica-
tions. Am J Clin Proc 1:51–57
26. Pascual J, Lainez JM, Leira R et al
(2003) Almotriptan in the treatment of
migraine attacks in clinical practice:
results of the TEA 2000 observational
study. Neurologia 18:7–17
27. Pascual J, Tranche S, Leira R et al
(2003) Almotriptan in clinical practice:
experience in primary care vs neurolo-
gy setting. Headache 43:525
28. Diener HC (2005) Consistent efficacy,
tolerability, and high levels of satisfac-
tion with almotriptan 12.5 mg when
used to treat multiple migraine attacks
in routine clinical practice. Headache
45:624–631
29. Massiou H, Pradalier A, Donnet A,
Lanteri-Minet M, Allaf B (2005)
Evaluation of efficacy, tolerability, and
treatment satisfaction with almotriptan
in 3 consecutive migraine attacks:
MIgraine – Satisfaction with
Treatment: Reality with ALmogran
(MISTRAL) study. Eur Neurol (in
press)
30. Geraud G, Lanteri-Minet M, Lucas C,
Valade D (2004) French guidelines for
the diagnosis and management of
migraine in adults and children. Clin
Ther 26:1305–1318
31. Gallagher RM, Kunkel R (2003)
Migraine medication attributes impor-
tant for patient compliance: concerns
about side effects may delay treatment.
Headache 43:36–44
32. Dodick DW (2001) Oral almotriptan in
the treatment of migraine: safety and
tolerability. Headache 41:449–455
